About sanofi - SNYNF
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines and vaccines franchises plus support and corporate functions, for all geographical territories. The company was founded in 1973 and is headquartered in Paris, France.
SNYNF At a Glance
Sanofi
46, avenue de la Grande Armée
Paris, Ile-de-France 75017
| Phone | 33-1-53-77-40-00 | Revenue | 49.24B | |
| Industry | Pharmaceuticals: Major | Net Income | 8.82B | |
| Sector | Health Technology | 2025 Sales Growth | 10.798% | |
| Fiscal Year-end | 12 / 2026 | Employees | N/A | |
| View SEC Filings |
SNYNF Valuation
| P/E Current | 13.032 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 13.446 |
| Price to Sales Ratio | 2.408 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | 9.77 |
| Enterprise Value to EBITDA | N/A |
| Enterprise Value to Sales | 2.718 |
| Total Debt to Enterprise Value | 0.178 |
SNYNF Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | N/A |
| Receivables Turnover | 105.597 |
| Total Asset Turnover | 0.344 |
SNYNF Liquidity
| Current Ratio | 1.092 |
| Quick Ratio | N/A |
| Cash Ratio | 0.27 |
SNYNF Profitability
| Gross Margin | 70.089 |
| Operating Margin | 32.666 |
| Pretax Margin | 14.154 |
| Net Margin | 17.909 |
| Return on Assets | 3.892 |
| Return on Equity | 6.794 |
| Return on Total Capital | 5.175 |
| Return on Invested Capital | 5.675 |
SNYNF Capital Structure
| Total Debt to Total Equity | 28.482 |
| Total Debt to Total Capital | 22.168 |
| Total Debt to Total Assets | 16.032 |
| Long-Term Debt to Equity | 22.017 |
| Long-Term Debt to Total Capital | 17.136 |